CD4 and pancreatic neoplasm: In patients with pancreatic cancer, a mutated Ras‐SLP was aimed to predominately activate CD4+ T cells can be synergized with GM‐CSF and mediate a robust CD4+ T cell response to prolong survival,360, 395 underlining the crucial role of MHC‐II‐restricted epitopes in immunotherapies.